RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Research and Development

A collection of news and information related to Research and Development published by this site and its partners.

Top Research and Development Articles

Displaying items 12-22
  • A plan for building Maryland's economy [Commentary]

    A plan for building Maryland's economy [Commentary]
    Earlier this General Assembly session, we joined together to announce a transformational economic development commission, a part of a joint economic development agenda that builds on the strategic investments Gov. Martin O'Malley and the legislature...
  • Letters: Paying big bucks to Big Pharma

    Re "Prices of new drugs tough to take," March 10 I understand the necessity for drug companies to recoup research and development costs. But in regard to a medication that can cure hepatitis C, a spokesman for the maker of one drug that costs about $1,...
  • Allergan employees, Irvine officials worried over Valeant offer

    Allergan employees, Irvine officials worried over Valeant offer
    Wall Street sharks are not the only ones keeping a close watch on the contentious battle for control of Allergan Inc., the Irvine company that makes Botox. So are thousands of the company's scientists and researchers, many of whose jobs may be at risk....
  • U.S. lead in science research and development narrows

    U.S. lead in science research and development narrows
    WASHINGTON – The United States could be losing its edge in science and technology as emerging nations rapidly increase their investment in research and development, according to new indicators┬áreleased Thursday by the National Science Board....
  • Interim nuclear deal allows Iran to continue centrifuge research

    WASHINGTON – The interim nuclear deal between Iran and world powers will allow Tehran to continue far more research and development on centrifuges to enrich uranium than has been publicly recognized, according to a veteran Washington nuclear...
  • Allergan questions viability, experience of would-be buyer Valeant

    A day before would-be buyer Valeant Pharmaceuticals is set to unveil a second, unsolicited takeover bid, its acquisition target, Allergan Inc., sought to discredit the company by filing a presentation with regulators questioning the viability of Valeant's...
  • Allergan steps up attack on Valeant

    The billion-dollar takeover battle targeting Irvine-based Allergan is heading into high gear this week with both sides on the attack. On Tuesday, Allergan Inc., the maker of Botox, launched a broadside against Canadian rival Valeant Pharmaceutics...
  • Valeant hikes its takeover offer for Allergan

    For weeks, Valeant Pharmaceuticals had promised a better offer for Botox maker Allergan, but its renewed cash-and-stock offer fell flat with investors and analysts. After Irvine-based Allergan Inc. rejected a $46-billion offer earlier this month, the...
  • In Fort Lauderdale, art on the margins

    In Fort Lauderdale, art on the margins
    When she unveils her project later this summer at the NSU Museum of Art Fort Lauderdale, Antonia Wright will have given voices to the homeless. She means that literally: Over the next two months, the Miami performance artist will have visited Broward...
  • Regional additive manufacturing authority established in Harford

    Gov. Martin O'Malley signed a bill Thursday creating a regional 3D printing and additive manufacturing authority in collaboration with the Edgewood Chemical Biological Center at Aberdeen Proving Ground. The bill, creating the Northeast Maryland Additive...
  • Pfizer's interest in AstraZeneca worries Maryland

    Pfizer's interest in AstraZeneca worries Maryland
    Research labs closed by pharmaceutical giant Pfizer dot the country: Illinois. Michigan. New Jersey. New York. North Carolina. Maryland officials don't want this state to join that list. After Pfizer declared its desire to buy AstraZeneca — which...